What is Phenotypic Screening?

Phenotypic screening is a strategy used in drug discovery to identify molecules that alter the phenotype of cells. Animal models and cell-based assays are both strategies used to identify these molecules. Phenotype-based drug screening (PDS) strategies facilitate the discovery of a class of first-in-class small molecule drugs. In contrast to target-based drug discovery, phenotypic screening does not rely on knowledge of the identity of a particular drug target or its putative role in disease. A key advantage of this approach over target-based screening is its ability to capture complex biological mechanisms that cannot be achieved with other methods.

Fig.1. Schematic representation of phenotype-based drug screening strategy. (Kumari A, et al., 2022)

Service Overview

Phenotypic screening is an attractive approach for identifying novel chemicals in therapeutic areas with complex ocular disease mechanisms or unknown disease targets. Ace Therapeutics' scientists can add significant value to your phenotype discovery program by leveraging their breadth and depth of knowledge across multiple ocular disease areas to design appropriate phenotypic assays and, when needed, quickly deconvolute phenotypic screens.

At Ace Therapeutics, we offer experience establishing phenotypic screens with a range of assay platforms, such as live cell imaging and  ocular disease live animals high content imaging.

What do We Provide?

Phenotypic screening run in healthy or disease-relevant primary cell models can help reduce attrition rates typically observed in target-based screens and identify new targets. At Ace Therapeutics, we have extensive experience running phenotypic screens using basal cell lines or relevant models of major health and eye diseases. Phenotype-based screening services developed by our talented scientists further complement the range of in-house target-based screening services available to our clients by combining ocular disease phenotype and genomic data to drive the potential benefits of small molecule drug discovery in ophthalmology hit finding method.

• In Vivo Phenotype Screening Assay Services

As a leader in the field of ophthalmology, we have developed dozens of live animal models of eye diseases for compound screening. Our broad portfolio of mouse, zebrafish phenotyping assays provides a means to assess phenotypes produced by pharmacological treatments and/or genetic variants of ophthalmic small molecule drugs in the whole organism for lead compound identification and ocular Disease disease biology understanding. Our live animal-based phenotypic screening services allow efficient in vivo efficacy testing. Taking the zebrafish model as an example,

• Cell-Based (In Vitro) Phenotypic Screening Services

Cell-based (in vitro) phenotypic screening services have significant advantages and can be easily adapted to high-throughput formats for automated phenotyping. Ace Therapeutics uses a novel phenotypic screening platform that combines the attributes of flow cytometry, HTS, and a powerful data analysis and management system into one platform. This optimized screening format can quickly identify hits from multiple compounds, greatly improving the chances of successful drug screening.

Ace Therapeutics provides high-quality phenotypic screening services for the development of small molecule targeted drugs in ophthalmology to customers around the world, thereby significantly reducing costs and facilitating further experiments. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

1. Kumari A, Zeng XA, Rahaman A, et al. Phenotype-based drug screening: An in vivo strategy to classify and identify the chemical compounds modulating zebrafish M-cell regeneration. Front Mol Biosci. 2022;9:984461.
2. Quint WH, Tadema KCD, Crins JHC,et al. Zebrafish: An In Vivo Screening Model to Study Ocular Phenotypes. Transl Vis Sci Technol. 2022;11(3):17.

• Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Ligand-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Fragment-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Phenotype-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• High Throughput Screening Services for Small Molecule Ophthalmic Drug Development
• Computer-Aided Screening Services for Small Molecule Ophthalmic Drug Development
• Ocular Diseases Small Molecules Compound Library

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit